Nasdaq

AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

- Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC - - Outcomes Favor Tivozanib in Patients Previously ...
Nasdaq

AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or ...

- Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up - - Analysis of TEAEs in TIVO-3 Study ...
BioWorld

AVEO, Astellas Seek to Hang Tivozanib Hat on PFS Data

AVEO Pharmaceuticals Inc. and partner Astellas Pharma Inc. reported top-line data from the global, randomized Phase III TIVO-1 trial indicating that lead compound tivozanib demonstrated superiority ...
Business Wire

AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All ...
Fierce Healthcare

AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference

Company, Media and Investor Contact:Argot PartnersDavid Pitts, 212-600-1902 AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company ...
Business Wire

AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma - Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and ...